Eli Lilly (NYSE: LLY) sells a broad range of pharmaceuticals treating various diseases, but one portfolio in particular has ...

An estimated 828 million adults (420 women, 408 men) had diabetes in 2022, an increase of 630 million since 1990. India (212 ...

Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends billions to ramp ...

Courts have long deferred to CMS’s decisions on implementation of laws that govern Medicare. The overturning of the Chevron ...

The tech company’s prices appear set to undercut the long list of competing telehealth companies that rely on aggressive ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...

Omega Therapeutics is halting work on its only clinical-stage candidate as part of a strategic refocus centered on three ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.

The disgruntled group demonstrated in Sandton on Thursday, led by humanitarian organisation, Doctors Without Borders.

In the world of health, Novo Nordisk stops insulin pen production, Trump's potential health appointments draw attention, and ...

Career mobility is one of the best things about working for a large company, especially one with offices across the globe. Diego Moreno, a health economics manager at Novo Nordisk Canada Inc. (NNCI), ...

For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) ...